Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced ...

Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and Drug ...

On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of drugs for schizophrenia in more than 30 years.

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

The FDA on Thursday approved the first new drug to treat patients with schizophrenia in more than 30 years.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

FDA approves a novel drug for schizophrenia, a potential ‘game changer’ Cobenfy showed in clinical trials that it was effective without causing common side effects that lead patients to stop ...

The FDA has approved a new type of schizophrenia drug that may change the way the disorder is treated.

Sept. 26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral ...